ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

DDDD 4d Pharma Plc

16.36
0.00 (0.00%)
Last Updated: 00:00:00
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
4d Pharma Plc LSE:DDDD London Ordinary Share GB00BJL5BR07 ORD 0.25P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 16.36 - 0.00 00:00:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
0 0 N/A 0

4d Pharma Share Discussion Threads

Showing 26 to 46 of 39325 messages
Chat Pages: Latest  13  12  11  10  9  8  7  6  5  4  3  2  Older
DateSubjectAuthorDiscuss
22/5/2015
09:19
...Anything is possible here.

Especially with Woodford increasing to 19.1% holding this month.

someuwin
22/5/2015
07:50
£15 coming soon.
blueball
22/5/2015
07:05
Moving up again.
someuwin
21/5/2015
14:51
Stock tightly held.

All buys are pushing it up.

someuwin
21/5/2015
11:28
£10+ today
someuwin
21/5/2015
10:23
I am convinced DDDD is in the process of being bought out. Very soon the buyer will come out with a full offer - imo.

At that point the spotlight will fall on OPTI as the only other microbiome player on the london market.

someuwin
20/5/2015
06:11
20 May 2015

4D pharma plc

(the "Company" or "4D")

Research Update on Clinical Development

4D pharma plc (AIM: DDDD), a pharmaceutical company focusing on the development of live biotherapeutics, today provides the following research update on its Clinical Development Programmes.

The Company currently has two programmes progressing towards the clinic, Blautix, for the treatment of Irritable Bowel Syndrome ("IBS"), and Thetanix, for the treatment of Paediatric Crohn's Disease.

The Board of the Company is pleased to report that a dossier for Blautix has been submitted to Swissmedic (Swiss Agency for Therapeutic Products) and the EKNZ (Swiss ethics committee) in relation to a first in man study to be carried out in healthy volunteers and individuals exhibiting symptoms of IBS.

Thetanix also continues to progress towards a first in man study, to be carried out in Paediatric Crohn's patients. Following a development programme to further optimise the Thetanix drug product, it is now anticipated that this trial will commence in H2 2015.

Dr. Alex Stevenson, 4D's Chief Scientific Officer, commented "4D is at the forefront of the development of live biotherapeutics, a new class of drug designed to treat the underlying causes of disease rather than just the symptoms. A critical component of making live biotherapeutics a reality is the ability to rapidly translate candidates identified in the laboratory into pharmaceutical grade products that can be administered to patients. Over the last few months we have made tremendous progress in establishing a methodology that allows us to do just that. With Blautix and Thetanix approaching the clinic, we are applying this same methodology to our pipeline of novel live biotherapeutic treatments for additional indications, such as asthma and rheumatoid arthritis, in line with our goal of developing ground breaking treatments for a wide range of important diseases".

someuwin
15/5/2015
10:15
...Still all buys.
someuwin
14/5/2015
10:04
All buys so far today.

Should move up again soon.

someuwin
13/5/2015
11:25
I reckon 1000p a share very soon.
blueball
13/5/2015
10:54
Guys also have a look at OPTI. Same sector as 4D but only valued at £26 million with commercial deals on the way.But well done with DDDD wish I'd seen it earlier.
talkingtrades
13/5/2015
10:52
Woodford also bought 15% of UTW
tjbird
13/5/2015
10:49
Can't get a live price for just £1k worth.

This will be moving higher imo.

someuwin
13/5/2015
10:29
Over £8 now.
someuwin
07/5/2015
06:16
Woodford increases holding again - now 19.1%.
someuwin
26/4/2015
16:06
Thanks someuwin. I have already bought into OPTI where the valuation seems far less hyped.
I guess it is all about leaps of faith!

plasybryn
26/4/2015
16:04
...It's all about the new field of science treating diseases by modifying the human microbiome.

(If you want a cheaper alternative look at OptiBiotix (OPTI). Same science but valued at only £30m vs. DDDD's £400m.)

Both could multiply from these levels.

"David Norwood, Chairman of 4D, commented that: "Our library of bacteria is extensive, putting 4D in a world leading position in being able to continue to mine for therapeutics that could have a curative effect in a variety of important diseases with significant unmet needs. The ability of the MicroRx platform to rationally select bacteria from this library and demonstrate therapeutically relevant effects in models of disease in a matter of months is extraordinary. This is not only a significant step forward for 4D, but also the area of live biotherapeutics in general, demonstrating that the microbiome potentially has a significant role to play in disease and its treatment."

someuwin
26/4/2015
15:45
I don't understand this stock.
The Market Cap. is enormous.
What makes it so valuable.
Is it all on a promise?

plasybryn
22/4/2015
14:04
Woodford adds another million DDDD shares taking him to 18.7%.
someuwin
14/4/2015
18:41
£14million cash in the bank and, maybe, good prospects
illtud
14/4/2015
17:17
amazing 1/2 bil pound cap no profit
tom111
Chat Pages: Latest  13  12  11  10  9  8  7  6  5  4  3  2  Older

Your Recent History

Delayed Upgrade Clock